Skip to content

Clinical trials

Observational Gastrointestinal Hemorrhage trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Gastrointestinal Hemorrhage Phase: Observational Clear all

118 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20021
20041
20061
20071
20082
20092
20106
20117
20122
20133
20146
20155
20164
20174
20185
20198
20205
20218
20228
20239
202410
202510
20269

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed57
Unknown status22
Not yet recruiting14
Recruiting14
Terminated5
Withdrawn3
Enrolling by invitation2
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Assiut University11
Bayer4
AstraZeneca3
Hôpital Universitaire Sahloul3
Sohag University3
AdventHealth2
Assistance Publique - Hôpitaux de Paris2
Beijing 302 Hospital2
Chinese University of Hong Kong2
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Gastrointestinal Hemorrhage118
Hemorrhage9
Atrial Fibrillation7
Acute Coronary Syndrome6
Intracranial Hemorrhages6
Venous Thrombosis6
Emergencies5
Pulmonary Embolism5
Gastrointestinal Diseases4
Stroke4

Trials

Showing 51 to 75 of 118. Each trial links to its page on Pharma Observatory.

18 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.